(Q58065005)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

title

Immunomodulators as adjunctive therapy for HIV-1 infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

author name string

S L Pett

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

publication date

1 October 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Virology

11 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

page(s)

289-295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with </=250/microL CD4 T cells and undetectable plasma virus load

11 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Effects of therapy with highly active anti-retroviral therapy (HAART) and IL-2 on CD4+ and CD8+ lymphocyte apoptosis in HIV+ patients

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol-modified interleukin-2 in human immunodeficiency virus-infected patients: a randomized, controlled, multicenter study. Australian IL-2 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Randomised trial of MNrgp120 HIV-1 vaccine in symptomless HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Toward HIV eradication or remission: the tasks ahead

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Longer-term immunologic effects and side effects of successful antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Interleukin-2: inception, impact, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Closeout of four phase II Vanguard trials and patient rollover into a large international phase III HIV clinical endpoint trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

1 reference

https://api.crossref.org/works/10.1016%2FS1386-6532%2801%2900201-3

7 January 2021

10.1016/S1386-6532(01)00201-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11564594%20AND%20SRC:MED&resulttype=core&format=json

11 November 2019

1 reference